ISHLT issues new guidelines for care of mechanical circulatory support device patients

(Elsevier Health Sciences) The International Society for Heart and Lung Transplantation convened an international panel of experts in all aspects of mechanical circulatory support care (MCS), a rapidly growing technology to treat advanced heart failure. They developed practice guidelines to provide a common framework for the care and treatment of MCS patients. The Executive Summary of these guidelines is published in the February issue of The Journal of Heart and Lung Transplantation and is freely available.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news

Related Links:

V-Wave said today it launched a new trial of its minimally invasive interartrial shunt designed to treat patients with symptomatic heart failure. The new Relieve-HF trial aims to enroll 500 patients in a pivotal study of the device, which is designed for patients with NHYA Class III and ambulatory Class IV symptomatic heart failure, the Israel-based company said. “The interatrial shunt provides a novel therapeutic approach for patients with chronic HF. The shunt is implanted through a catheter inserted in a vein in the leg. Prior clinical experience demonstrated device and implantation procedure safety, and stat...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Clinical Trials V-Wave Source Type: news
Background: The outlook for ambulatory patients with advanced heart failure (HF) and the appropriate timing for left ventricular assist device (LVAD) or transplant remain uncertain. The aim of this study was to better understand disease trajectory and rates of progression to subsequent LVAD therapy and transplant in ambulatory advanced HF.Methods: Patients with advanced HF who were NYHA class III-IV and Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Profiles 4-7 despite optimal medical therapy (without inotropic therapy) were enrolled across 11 centers and followed for the end-points of surv...
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
Heart transplantation is the preferred treatment strategy for patients suffering from end stage heart failure. This treatment offers the most beneficial survival outcome and improvement of life quality for heart failure patients and each year the number of transplantations performed increases. However, a growing number of patients requiring heart transplantation are indefinitely waitlisted due to the scarcity of donor hearts.1 The latest available Annual Data Report, by the Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients shows that only 50% of the candidates waitlisted through...
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
ConclusionsSimilar incidents could occur, as rates of hate crimes and support for racial profiling increase. Thus, this report calls for greater recognition of the challenge of living with the LVAD by clinicians, leading to better patient education and increased access to psychological therapy. There is also an avenue for national bodies to develop greater awareness of LVAD and improve access to psychological support.
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research
Markers of disease chronicity are useful tools in a variety of diseases. For example, in diabetes, the glycated hemoglobin (hemoglobin A1c) level reflects chronic glucose management. With heart failure, markers of acute decompensations, such as pro-brain naturietic peptide (pro-BNP) levels and altered hemodynamics, do not readily predict the chronic condition, nor do they predict heart failure stage in the compensated state.1 In this issue of the Journal, Chimura and colleagues at Osaka University in Japan look for new clues to predict heart failure progression in a population of New York Heart Association (NYHA) Functiona...
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Editorial Source Type: research
Right heart failure (RHF) remains an Achilles ’ heel of durable left ventricular assist device (LVAD) therapy.1 Not only are pre-operative predictors for RHF difficult to develop and apply, but the emergence of unique phenotypes of late-onset RHF continue to perplex clinicians.2 Prediction models to reliably define need for intraoperative rig ht ventricular support have been difficult to develop, lack sufficient predictive capability, and clinicians are left to use intraoperative decisional tools based on hemodynamic outcomes during implantation of a left-sided device or within hours to days after surgery.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: EDITORIAL Source Type: research
Right heart failure (RHF) remains an Achilles heel of durable left ventricular assist device (LVAD) therapy.1 Not only are pre-operative predictors for RHF difficult to develop and apply but the emergence of unique phenotypes of late onset RHF continue to perplex clinicians.2 Prediction models to reliably define need for intraoperative right ventricular support have been difficult to develop, lack sufficient predictive capability and clinicians are left to employ intraoperative decisional tools based on hemodynamic outcomes during implantation of a left sided device or within hours to days following surgery.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Editorial Source Type: research
The syndrome of frailty for patients undergoing heart or lung transplantation has been a recent focus for perioperative clinicians because of its association with postoperative complications and poor outcomes. Patients with end-stage cardiac or pulmonary failure may be under consideration for heart or lung transplantation along with bridging therapies such as ventricular assist device implantation or venovenous extracorporeal membrane oxygenation, respectively. Early identification of frail patients in an attempt to modify the risk of postoperative morbidity and mortality has become an important area of study over the last decade.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Review Article Source Type: research
Despite over 50 years of intra-aortic balloon pump (IABP) use, the role of this device to treat patients with cardiogenic shock (CS) is not clearly defined. Based on the results of the IABP-SHOCK II trial,1 recommendations to treat acute and chronic heart failure (HF) complicated by CS with an IABP are either lacking or clearly state to not use this therapy.2 In this issue of the Journal, Fried et al. report the largest single center examination of IABP use in this specific patient population.3
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Editorial Source Type: research
Authors: Previato M, Osto E, Kerkhof PLM, Parry G, Tona F Abstract Orthotopic heart transplantation (OHT) is the "gold standard" treatment for patients with end-stage heart failure, with approximately 5000 transplants performed each year worldwide. Heart transplantation survival rates have progressively improved at all time points, despite an increase in donor and recipient age and comorbidity and greater recipient urgency; according to the registry of the International Society of Heart and Lung Transplantation (ISHLT), the median survival of patients posttransplantation is currently 12.2 years.Long-...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
More News: Cardiology | Health | Heart | Heart Failure | Heart Transplant | International Medicine & Public Health | Lung Transplant | Transplants